Cold but not sympathomimetics activates human brown adipose tissue in vivo

As potential activators of brown adipose tissue (BAT), mild cold exposure and sympathomimetic drugs have been considered as treatments for obesity and diabetes, but whether they activate the same pathways is unknown. In 10 healthy human volunteers, we found that the sympathomimetic ephedrine raised...

Full description

Saved in:
Bibliographic Details
Published inProceedings of the National Academy of Sciences - PNAS Vol. 109; no. 25; pp. 10001 - 10005
Main Authors Cypess, Aaron M, Chen, Yih-Chieh, Sze, Cathy, Wang, Ke, English, Jeffrey, Chan, Onyee, Holman, Ashley R, Tal, Ilan, Palmer, Matthew R, Kolodny, Gerald M, Kahn, C. Ronald
Format Journal Article
LanguageEnglish
Published United States National Academy of Sciences 19.06.2012
National Acad Sciences
Subjects
Online AccessGet full text
ISSN0027-8424
1091-6490
1091-6490
DOI10.1073/pnas.1207911109

Cover

More Information
Summary:As potential activators of brown adipose tissue (BAT), mild cold exposure and sympathomimetic drugs have been considered as treatments for obesity and diabetes, but whether they activate the same pathways is unknown. In 10 healthy human volunteers, we found that the sympathomimetic ephedrine raised blood pressure, heart rate, and energy expenditure, and increased multiple circulating metabolites, including glucose, insulin, and thyroid hormones. Cold exposure also increased blood pressure and energy expenditure, but decreased heart rate and had little effect on metabolites. Importantly, cold increased BAT activity as measured by ¹⁸F-fluorodeoxyglucose PET-CT in every volunteer, whereas ephedrine failed to stimulate BAT. Thus, at doses leading to broad activation of the sympathetic nervous system, ephedrine does not stimulate BAT in humans. In contrast, mild cold exposure stimulates BAT energy expenditure with fewer other systemic effects, suggesting that cold activates specific sympathetic pathways. Agents that mimic cold activation of BAT could provide a promising approach to treating obesity while minimizing systemic effects.
Bibliography:http://dx.doi.org/10.1073/pnas.1207911109
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 14
ObjectType-Article-1
ObjectType-Feature-2
content type line 23
Contributed by C. Ronald Kahn, May 9, 2012 (sent for review March 17, 2012)
Author contributions: A.M.C. and C.R.K. designed research; A.M.C., Y-C.C., C.S., K.W., J.E., A.R.H., M.R.P., and G.M.K. performed research; I.T. contributed new reagents/analytic tools; A.M.C., Y-C.C., C.Z., K.W., O.C., M.R.P., and G.M.K. analyzed data; and A.M.C. and C.R.K. wrote the paper.
ISSN:0027-8424
1091-6490
1091-6490
DOI:10.1073/pnas.1207911109